339 related articles for article (PubMed ID: 9826984)
1. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
[TBL] [Abstract][Full Text] [Related]
2. [Medical treatment of spasticity].
Rode G; Maupas E; Luaute J; Courtois-Jacquin S; Boisson D
Neurochirurgie; 2003 May; 49(2-3 Pt 2):247-55. PubMed ID: 12746699
[TBL] [Abstract][Full Text] [Related]
3. Traditional pharmacological treatments for spasticity. Part I: Local treatments.
Gracies JM; Elovic E; McGuire J; Simpson DM
Muscle Nerve Suppl; 1997; 6():S61-91. PubMed ID: 9826983
[TBL] [Abstract][Full Text] [Related]
4. [Orally administered drugs in the treatment of spasticity].
Campistol J
Rev Neurol; 2003 Jul 1-15; 37(1):70-4. PubMed ID: 12861514
[TBL] [Abstract][Full Text] [Related]
5. Comparative profile of tizanidine in the management of spasticity.
Lataste X; Emre M; Davis C; Groves L
Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
[TBL] [Abstract][Full Text] [Related]
6. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials of botulinum toxin in the treatment of spasticity.
Simpson DM
Muscle Nerve Suppl; 1997; 6():S169-75. PubMed ID: 9826988
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
9. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
10. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Wagstaff AJ; Bryson HM
Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
Kofler M; Quirbach E; Schauer R; Singer M; Saltuari L
Neurorehabil Neural Repair; 2009 Jan; 23(1):26-31. PubMed ID: 18796543
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of spasticity with the intrathecal administration of baclofen].
Lazorthes Y; Sallerin B; Verdié JC; Casaux J; Caraoué F; Sol JC
Neurochirurgie; 1998 Sep; 44(3):201-8. PubMed ID: 9827437
[TBL] [Abstract][Full Text] [Related]
14. Functional outcome of intrathecal baclofen administration for severe spasticity.
Boviatsis EJ; Kouyialis AT; Korfias S; Sakas DE
Clin Neurol Neurosurg; 2005 Jun; 107(4):289-95. PubMed ID: 15885386
[TBL] [Abstract][Full Text] [Related]
15. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
[TBL] [Abstract][Full Text] [Related]
16. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
Lapeyre E; Kuks JB; Meijler WJ
NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke].
Lamotte D; Cantalloube S
Ann Readapt Med Phys; 2007 Apr; 50(3):165-9. PubMed ID: 17145092
[TBL] [Abstract][Full Text] [Related]
18. [Spasticity treatment with spinal morphine or midazolam. In vitro experiments, animal studies and clinical studies on compatibility and effectiveness].
Müller H; Gerlach H; Boldt J; Börner U; Hild P; Oehler KU; Zierski J; Hempelmann G
Anaesthesist; 1986 May; 35(5):306-16. PubMed ID: 2943190
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
Mathias CJ; Luckitt J; Desai P; Baker H; el Masri W; Frankel HL
J Rehabil Res Dev; 1989; 26(4):9-16. PubMed ID: 2600869
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological interventions for spasticity following spinal cord injury.
Taricco M; Adone R; Pagliacci C; Telaro E
Cochrane Database Syst Rev; 2000; 2000(2):CD001131. PubMed ID: 10796750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
